What is on the horizon for the frontline treatment of MCL?
Lymphoma Hub25 Heinä 2022

What is on the horizon for the frontline treatment of MCL?

During the ASCO2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatment of mantle cell lymphoma (MCL)?


Kumar begins by discussing the historic treatment options for patients with MCL before highlighting that, in the future, clinicians hope to utilize information on clinical and biological baseline features that patients present with, and incorporate novel targeted therapies and MRD assessments to further individualize treatment for MCL. Kumar describes how increased pathobiological understanding has led to developments in the relapsed/refractory setting; results of studies, such as SHINE, have explored this. Finally, Kumar discusses other therapeutic options and outlines adverse events and efficacy seen in the current OASIS phase III trial.

Hosted on Acast. See acast.com/privacy for more information.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(53)

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

20 Elo 23min

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas S...

12 Elo 27min

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

12 Elo 12min

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel ...

21 Heinä 8min

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We...

16 Heinä 10min

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating za...

10 Heinä 26min

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, W...

1 Heinä 5min

Annual oncology meeting | Key highlights in lymphoma

Annual oncology meeting | Key highlights in lymphoma

During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount ...

22 Kesä 11min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
psykopodiaa-podcast
aamukahvilla
adhd-podi
voi-hyvin-meditaatiot-2
rss-rahamania
rss-vapaudu-voimaasi
rss-niinku-asia-on
rss-liian-kuuma-peruna
rss-koira-haudattuna
rss-keskeneraiset-aidit
kesken
koulu-podcast-2
ihminen-tavattavissa-tommy-hellsten-instituutti
rss-uskonto-on-tylsaa
rss-arkea-ja-aurinkoa-podcast-espanjasta
rahapuhetta
puhutaan-koiraa
rss-varapare
rss-duodecim-lehti